Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRIS: Immunosenescence in Chronic Kidney Disease
NCT02116270Completed
- Sponsor
- CHU de Besançon
- Start
- Sep 2013
- Primary completion
- Aug 2016
- Countries
- 1
01
Overview
Open-label trial (4 arms), sponsored by CHU de Besançon. Primary endpoint: Percentage of Cluster of Differentiation (CD) 4/8+ CD 57+ CD 28- lymphocytes at 6 months. Started Sep 2013; status: completed.
Beyond the preview
Go deeper on NCT02116270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02116270.